JP7569443B2 - テトラヒドロピラゾロ－ピラジニル－ジヒドロイミダゾロンまたはテトラヒドロピラゾロ－ピリジニル－ジヒドロイミダゾロン化合物およびそれを使用する方法 - Google Patents
テトラヒドロピラゾロ－ピラジニル－ジヒドロイミダゾロンまたはテトラヒドロピラゾロ－ピリジニル－ジヒドロイミダゾロン化合物およびそれを使用する方法 Download PDFInfo
- Publication number
- JP7569443B2 JP7569443B2 JP2023504008A JP2023504008A JP7569443B2 JP 7569443 B2 JP7569443 B2 JP 7569443B2 JP 2023504008 A JP2023504008 A JP 2023504008A JP 2023504008 A JP2023504008 A JP 2023504008A JP 7569443 B2 JP7569443 B2 JP 7569443B2
- Authority
- JP
- Japan
- Prior art keywords
- butyl
- butoxy
- propyl
- alkyl
- propoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024174734A JP7795064B2 (ja) | 2020-07-20 | 2024-10-04 | テトラヒドロピラゾロ－ピラジニル－ジヒドロイミダゾロンまたはテトラヒドロピラゾロ－ピリジニル－ジヒドロイミダゾロン化合物およびそれを使用する方法 |
| JP2025207454A JP2026035735A (ja) | 2020-07-20 | 2025-11-28 | テトラヒドロピラゾロ－ピラジニル－ジヒドロイミダゾロンまたはテトラヒドロピラゾロ－ピリジニル－ジヒドロイミダゾロン化合物およびそれを使用する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/102955 | 2020-07-20 | ||
| CN2020102955 | 2020-07-20 | ||
| CNPCT/CN2021/070120 | 2021-01-04 | ||
| CN2021070120 | 2021-01-04 | ||
| PCT/CN2021/107216 WO2022017338A1 (en) | 2020-07-20 | 2021-07-20 | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024174734A Division JP7795064B2 (ja) | 2020-07-20 | 2024-10-04 | テトラヒドロピラゾロ－ピラジニル－ジヒドロイミダゾロンまたはテトラヒドロピラゾロ－ピリジニル－ジヒドロイミダゾロン化合物およびそれを使用する方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023534983A JP2023534983A (ja) | 2023-08-15 |
| JP2023534983A5 JP2023534983A5 (https=) | 2024-07-29 |
| JPWO2022017338A5 JPWO2022017338A5 (https=) | 2024-07-29 |
| JP7569443B2 true JP7569443B2 (ja) | 2024-10-17 |
Family
ID=77167918
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504008A Active JP7569443B2 (ja) | 2020-07-20 | 2021-07-20 | テトラヒドロピラゾロ－ピラジニル－ジヒドロイミダゾロンまたはテトラヒドロピラゾロ－ピリジニル－ジヒドロイミダゾロン化合物およびそれを使用する方法 |
| JP2024174734A Active JP7795064B2 (ja) | 2020-07-20 | 2024-10-04 | テトラヒドロピラゾロ－ピラジニル－ジヒドロイミダゾロンまたはテトラヒドロピラゾロ－ピリジニル－ジヒドロイミダゾロン化合物およびそれを使用する方法 |
| JP2025207454A Pending JP2026035735A (ja) | 2020-07-20 | 2025-11-28 | テトラヒドロピラゾロ－ピラジニル－ジヒドロイミダゾロンまたはテトラヒドロピラゾロ－ピリジニル－ジヒドロイミダゾロン化合物およびそれを使用する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024174734A Active JP7795064B2 (ja) | 2020-07-20 | 2024-10-04 | テトラヒドロピラゾロ－ピラジニル－ジヒドロイミダゾロンまたはテトラヒドロピラゾロ－ピリジニル－ジヒドロイミダゾロン化合物およびそれを使用する方法 |
| JP2025207454A Pending JP2026035735A (ja) | 2020-07-20 | 2025-11-28 | テトラヒドロピラゾロ－ピラジニル－ジヒドロイミダゾロンまたはテトラヒドロピラゾロ－ピリジニル－ジヒドロイミダゾロン化合物およびそれを使用する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US12037339B2 (https=) |
| EP (1) | EP4182020A1 (https=) |
| JP (3) | JP7569443B2 (https=) |
| KR (2) | KR102936860B1 (https=) |
| CN (1) | CN116390926A (https=) |
| AU (2) | AU2021311567B2 (https=) |
| BR (1) | BR112023000932A2 (https=) |
| CA (1) | CA3186217A1 (https=) |
| CL (1) | CL2023000196A1 (https=) |
| CO (1) | CO2023001407A2 (https=) |
| IL (1) | IL299704A (https=) |
| MX (1) | MX2023000943A (https=) |
| PE (1) | PE20230854A1 (https=) |
| PH (1) | PH12023550130A1 (https=) |
| WO (1) | WO2022017338A1 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| EP4211139A4 (en) * | 2020-09-10 | 2024-12-18 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US20240366639A1 (en) * | 2021-08-12 | 2024-11-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| KR20240068737A (ko) | 2021-09-27 | 2024-05-17 | 테른스 파마슈티칼스, 인크. | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| KR20240150488A (ko) | 2022-02-23 | 2024-10-15 | 테른스 파마슈티칼스, 인크. | Glp-1r 작용제로서의 화합물 |
| IL316478A (en) * | 2022-05-11 | 2024-12-01 | Lilly Co Eli | GLP1 tablet preparations |
| CN116003403B (zh) * | 2022-11-20 | 2024-07-23 | 药康众拓(北京)医药科技有限公司 | 一种氘代吲唑类化合物、药物组合物及其应用 |
| EP4634156A1 (en) * | 2022-12-15 | 2025-10-22 | Sironax Ltd | Sarm1 modulators, preparations, and uses thereof |
| EP4652167A1 (en) * | 2023-01-17 | 2025-11-26 | Fochon Biosciences, Ltd. | Glp-1r agonists and uses thereof |
| AU2024222719A1 (en) | 2023-02-16 | 2025-08-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| JP2025538520A (ja) * | 2023-06-29 | 2025-11-28 | ウェイン バイオテクノロジー カンパニー，リミテッド | Ｇｌｐ－１受容体アゴニスト並びにその調製方法及び使用 |
| CN120574224A (zh) * | 2023-06-30 | 2025-09-02 | 正大天晴药业集团股份有限公司 | 含多稠环结构的化合物 |
| WO2025011664A1 (zh) | 2023-07-12 | 2025-01-16 | 歌礼制药(中国)有限公司 | Glp-1r激动剂的制剂及其制备方法 |
| CN121712771A (zh) * | 2023-07-28 | 2026-03-20 | 上海翰森生物医药科技有限公司 | 一种苯并含氮杂环类衍生物调节剂、其制备方法和应用 |
| WO2025026436A1 (zh) * | 2023-08-02 | 2025-02-06 | 韦恩生物科技有限公司 | 一种含氮并环化合物及其制备方法和用途 |
| WO2025045208A1 (en) * | 2023-08-31 | 2025-03-06 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| TW202521533A (zh) * | 2023-09-14 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025097835A1 (zh) | 2023-11-10 | 2025-05-15 | 重庆医药工业研究院有限责任公司 | 一种glp-1r激动剂化合物及其应用 |
| TW202527933A (zh) * | 2023-11-16 | 2025-07-16 | 大陸商西藏海思科製藥有限公司 | 咪唑-2-酮衍生物及其在醫藥上的應用 |
| WO2025108361A1 (zh) * | 2023-11-21 | 2025-05-30 | 江苏恒瑞医药股份有限公司 | 杂环类化合物、其制备方法及其在医药上的应用 |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025119206A1 (en) * | 2023-12-05 | 2025-06-12 | Fortvita Biologics Inc. | Glp-1 receptor targeting compounds and uses thereof |
| WO2025124357A1 (zh) * | 2023-12-14 | 2025-06-19 | 广东众生睿创生物科技有限公司 | 一种杂环glp-1受体激动剂及其应用 |
| TW202527937A (zh) * | 2023-12-22 | 2025-07-16 | 大陸商石藥集團百克（山東）生物製藥股份有限公司 | 多環化合物及其用途 |
| CN117447493A (zh) * | 2023-12-25 | 2024-01-26 | 药康众拓(北京)医药科技有限公司 | 氘代吲哚嗪类化合物、药物组合物及其应用 |
| CN117777111A (zh) * | 2023-12-26 | 2024-03-29 | 上海苏博医药科技有限公司 | 一种Orforglipron关键中间体的合成方法及其中间体 |
| WO2025148997A1 (zh) * | 2024-01-10 | 2025-07-17 | 海思科医药集团股份有限公司 | 一种四氢吡啶并吡唑衍生物及其在医药上的应用 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| CN120813584A (zh) * | 2024-01-30 | 2025-10-17 | 海创药业股份有限公司 | 一种具有glp-1受体激动剂作用的小分子化合物及其用途 |
| WO2025175249A1 (en) | 2024-02-14 | 2025-08-21 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| WO2025176130A1 (zh) * | 2024-02-19 | 2025-08-28 | 上海壹迪生物技术有限公司 | 一种含吡唑并环类化合物、其药物组合物及其用途 |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
| WO2025208111A1 (en) * | 2024-03-29 | 2025-10-02 | Biomea Fusion, Inc. | Heterocyclic glp-1r agonists |
| WO2025209515A1 (zh) * | 2024-04-03 | 2025-10-09 | 广州市联瑞制药有限公司 | 一种glp-1受体激动剂及其制备方法和应用 |
| WO2025237355A1 (zh) * | 2024-05-17 | 2025-11-20 | 成都地奥九泓制药厂 | 一种glp-1受体激动剂化合物、其制备方法及其应用 |
| WO2025247390A1 (zh) * | 2024-05-31 | 2025-12-04 | 福佑泰生物制药公司 | 可用作glp-1r激动剂的杂双环化合物 |
| WO2025259825A1 (en) | 2024-06-12 | 2025-12-18 | Eli Lilly And Company | Glp-1 npa therapies for maintaining body weight loss or reduced hba1c levels following a prior glp-1 ra treatment |
| WO2025261454A1 (zh) * | 2024-06-19 | 2025-12-26 | 上海翰森生物医药科技有限公司 | 一种含氮大环化合物衍生物调节剂及其制备方法和应用 |
| WO2025264023A1 (en) * | 2024-06-19 | 2025-12-26 | Chong Kun Dang Pharmaceutical Corp. | Glp-1 receptor agonist, and uses thereof |
| WO2026001866A1 (zh) * | 2024-06-24 | 2026-01-02 | 联邦生物科技(珠海横琴)有限公司 | 一种glp-1受体激动剂及其应用 |
| WO2026007995A1 (zh) * | 2024-07-03 | 2026-01-08 | 成都地奥九泓制药厂 | 一种杂环类glp-1受体激动剂化合物、其制备方法及其应用 |
| WO2026012416A1 (zh) * | 2024-07-11 | 2026-01-15 | 江苏德源药业股份有限公司 | 杂环类化合物、药物组合物及其应用 |
| WO2026012449A1 (zh) * | 2024-07-12 | 2026-01-15 | 联邦生物科技(珠海横琴)有限公司 | 一种具有glp-1受体激动剂效应的杂环化合物及其应用 |
| WO2026031819A1 (en) * | 2024-08-06 | 2026-02-12 | Insilico Medicine Ip Limited | Novel compounds as glp-1r agonists and uses thereof |
| WO2026041075A1 (en) * | 2024-08-21 | 2026-02-26 | Gasherbrum Bio, Inc. | Gpl-1 agonists |
| CN119100966B (zh) * | 2024-09-02 | 2025-09-09 | 上海毕得医药科技股份有限公司 | 一种溴代吡咯甲酸甲酯的合成方法 |
| WO2026055512A1 (en) * | 2024-09-05 | 2026-03-12 | Biomea Fusion, Inc. | Combination of a menin inhibitor with a pyrazolopiperidine glp-1 receptor agonist for treating diabetes and obesity |
| WO2026052129A1 (zh) * | 2024-09-09 | 2026-03-12 | 中国科学院上海药物研究所 | 多环杂芳烃类glp-1受体激动剂 |
| CN120309500B (zh) * | 2025-06-19 | 2025-08-15 | 南昌大学 | 奥格列龙原料中间体及合成方法与奥格列龙原料合成方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014133008A1 (ja) | 2013-02-27 | 2014-09-04 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するインドールおよびアザインドール誘導体 |
| WO2018056453A1 (ja) | 2016-09-26 | 2018-03-29 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
| WO2019166951A1 (en) | 2018-02-28 | 2019-09-06 | Novartis Ag | Indole-2-carbonyl compounds and their use for the treatment of hepatitis b |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP7461104B2 (ja) * | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
-
2021
- 2021-07-20 WO PCT/CN2021/107216 patent/WO2022017338A1/en not_active Ceased
- 2021-07-20 JP JP2023504008A patent/JP7569443B2/ja active Active
- 2021-07-20 US US17/380,084 patent/US12037339B2/en active Active
- 2021-07-20 KR KR1020237005845A patent/KR102936860B1/ko active Active
- 2021-07-20 PH PH1/2023/550130A patent/PH12023550130A1/en unknown
- 2021-07-20 AU AU2021311567A patent/AU2021311567B2/en active Active
- 2021-07-20 CN CN202180063652.8A patent/CN116390926A/zh active Pending
- 2021-07-20 BR BR112023000932A patent/BR112023000932A2/pt unknown
- 2021-07-20 IL IL299704A patent/IL299704A/en unknown
- 2021-07-20 KR KR1020267006827A patent/KR20260040657A/ko active Pending
- 2021-07-20 MX MX2023000943A patent/MX2023000943A/es unknown
- 2021-07-20 EP EP21749074.7A patent/EP4182020A1/en active Pending
- 2021-07-20 CA CA3186217A patent/CA3186217A1/en active Pending
- 2021-07-20 PE PE2023000103A patent/PE20230854A1/es unknown
- 2021-11-02 US US17/516,932 patent/US11584751B1/en active Active
-
2023
- 2023-01-19 CL CL2023000196A patent/CL2023000196A1/es unknown
- 2023-02-09 CO CONC2023/0001407A patent/CO2023001407A2/es unknown
-
2024
- 2024-05-14 US US18/663,450 patent/US20250059192A1/en active Pending
- 2024-10-04 JP JP2024174734A patent/JP7795064B2/ja active Active
-
2025
- 2025-09-24 AU AU2025237942A patent/AU2025237942A1/en active Pending
- 2025-11-28 JP JP2025207454A patent/JP2026035735A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014133008A1 (ja) | 2013-02-27 | 2014-09-04 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するインドールおよびアザインドール誘導体 |
| WO2018056453A1 (ja) | 2016-09-26 | 2018-03-29 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体 |
| US20190225604A1 (en) | 2016-09-26 | 2019-07-25 | Chugai Seiyaku Kabushiki Kaisha | Pyrazolopyridine derivative having glp-1 receptor agonist effect |
| WO2019166951A1 (en) | 2018-02-28 | 2019-09-06 | Novartis Ag | Indole-2-carbonyl compounds and their use for the treatment of hepatitis b |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250059192A1 (en) | 2025-02-20 |
| JP2025004124A (ja) | 2025-01-14 |
| KR20230048056A (ko) | 2023-04-10 |
| IL299704A (en) | 2023-03-01 |
| US11584751B1 (en) | 2023-02-21 |
| JP2026035735A (ja) | 2026-03-04 |
| PE20230854A1 (es) | 2023-05-29 |
| MX2023000943A (es) | 2023-02-22 |
| EP4182020A1 (en) | 2023-05-24 |
| JP7795064B2 (ja) | 2026-01-07 |
| AU2021311567A1 (en) | 2023-02-16 |
| KR102936860B1 (ko) | 2026-03-12 |
| US20230051320A1 (en) | 2023-02-16 |
| AU2021311567B2 (en) | 2025-07-10 |
| WO2022017338A1 (en) | 2022-01-27 |
| BR112023000932A2 (pt) | 2023-10-03 |
| US12037339B2 (en) | 2024-07-16 |
| CA3186217A1 (en) | 2022-01-27 |
| CO2023001407A2 (es) | 2023-02-16 |
| PH12023550130A1 (en) | 2024-06-24 |
| CL2023000196A1 (es) | 2023-09-15 |
| AU2025237942A1 (en) | 2025-10-16 |
| CN116390926A (zh) | 2023-07-04 |
| KR20260040657A (ko) | 2026-03-25 |
| JP2023534983A (ja) | 2023-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7569443B2 (ja) | テトラヒドロピラゾロ－ピラジニル－ジヒドロイミダゾロンまたはテトラヒドロピラゾロ－ピリジニル－ジヒドロイミダゾロン化合物およびそれを使用する方法 | |
| TWI855062B (zh) | Bcl-2抑制劑 | |
| JP7811578B2 (ja) | 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用 | |
| US20220348564A1 (en) | Phenyl-[1,3]dioxolo[4,5-c]pyridinyl-phenyl-, phenyl-[1,3]dioxolo[4,5-c]pyridinyl-heteroaryl-, or phenyl-(1,3)dioxo[4,5-c]pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo[d]imidazole-carboxylic acid derivatives and methods of using same | |
| CN105121426B (zh) | 吡咯烷gpr40调节剂 | |
| CN112566637A (zh) | Glp-1受体激动剂及其用途 | |
| CN109111451B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| WO2021078301A1 (zh) | 蛋白降解剂及其在疾病治疗中的应用 | |
| CN112174935A (zh) | 可用作shp2抑制剂的新型杂环衍生物 | |
| AU2024206693A1 (en) | Shp2 inhibitor and uses thereof | |
| CN113072542A (zh) | RORγt抑制剂及其制备方法和用途 | |
| CN113754654A (zh) | 咪唑并吡啶类化合物及其用途 | |
| JP2025528804A (ja) | イソインドリン置換グルタルイミド骨格に基づく化合物、及びその応用 | |
| CN107108625A (zh) | 螺环衍生物 | |
| JP2019510782A (ja) | ブロモドメイン阻害薬としてのピリジル誘導体 | |
| CN116113627A (zh) | 季吲哚糖皮质激素受体拮抗剂 | |
| CN106458987B (zh) | 用于治疗疾病诸如糖尿病的吡咯烷gpr40调节剂 | |
| JP7703272B2 (ja) | Ｓｓａｏ阻害剤およびその使用 | |
| BR122025022209A2 (pt) | Compostos de tetra-hidropirazolo-piridinil-di-hidroimidazolona, composição farmacêutica e seus usos | |
| CN114181205B (zh) | 吡唑并吡啶类化合物或其盐及其制备方法和用途 | |
| HK40069684A (en) | Pyrazolopyridine compounds or salts thereof and their preparation methods and uses | |
| EA049031B1 (ru) | Соединения тетрагидропиразоло-пиразинил-дигидроимидазолона или тетрагидропиразоло-пиридинил-дигидроимидазолона и способы их применения | |
| KR20250128310A (ko) | Hur 조절 화합물 (elavl1) | |
| WO2024067708A1 (zh) | 草酸胺类衍生物、包含其的药物组合物及其医药用途 | |
| HK40044822A (en) | Glp-1 receptor agonists and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230522 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20231208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240719 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240719 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20240719 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240808 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240904 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241004 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7569443 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |